Urology
Volume 64, Issue 2 , Pages 292-297, August 2004

Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older☆

  • Brent K Hollenbeck

      Affiliations

    • Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    • Corresponding Author InformationReprint requests: Brent K. Hollenbeck, Department of Urology, University of Michigan Medical Center, 1500 East Medical Center Drive, Taubman Center 2916H, Box 0330, Ann Arbor, MI 48109-0330, USA
    • ,
  • David C Miller

      Affiliations

    • Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    • ,
  • David Taub

      Affiliations

    • Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    • ,
  • Rodney L Dunn

      Affiliations

    • Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    • ,
  • Willie Underwood III

      Affiliations

    • Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    • ,
  • James E Montie

      Affiliations

    • Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    • ,
  • John T Wei

      Affiliations

    • Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan, USA

Received 3 February 2004; accepted 15 March 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ J. E. Montie is a study investigator funded by AstraZeneca. J. T. Wei is a paid consultant to Sanofi Synthelabo.

PII: S0090-4295(04)00406-6

doi:10.1016/j.urology.2004.03.034

Urology
Volume 64, Issue 2 , Pages 292-297, August 2004

Article Tools

* Image Usage & Resolution